Atypical hemolytic-uremic syndrome due to complement factor I mutation

Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3 Eculizumab para el tratamiento de un síndrome urémico hemolítico

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

To the Editor: Atypical hemolytic–uremic syndrome is a rare microangiopathic hemolytic condition characterized by thrombocytopenia and acute renal failure.1 The prognosis for patients with atypical hemolytic–uremic syndrome with a factor H mutation is poor; 60% have end-stage renal disease or die within a year.2 The expected rate of graft failure due to recurrent atypical hemolytic–uremic syndr...

Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3.

Diabetic ketoacidosis presenting with atypical hemolytic uremic syndrome associated with a variant of complement factor B in an adult: a case report

BACKGROUND Non-Shiga toxin-associated hemolytic uremic syndrome is known to be caused by dysregulation of the alternative complement pathway. Infections, drugs, pregnancy, bone marrow transplantation, malignancy, and autoimmune disorders have all been reported to trigger episodes of atypical hemolytic uremic syndrome. To the best of our knowledge, there have been no previous reports of an assoc...

Postoperative Atypical Hemolytic Uremic Syndrome Associated with Complement C3 Mutation

Atypical hemolytic uremic syndrome (aHUS) can be distinguished from typical or Shiga-like toxin-induced HUS. The clinical outcome is unfavorable; up to 50% of affected patients progress to end-stage renal failure and 25% die during the acute phase. Multiple conditions have been associated with aHUS, including infections, drugs, autoimmune conditions, transplantation, pregnancy, and metabolic co...